Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
L. Al-Nakkash, T. Janjulia, K. Peterson, D. Lucy, D. Wilson, A. Peterson, W. Prozialeck & T. L. Broderick. (2014) Genistein and exercise do not improve cardiovascular risk factors in the ovariectomized rat. Climacteric 17:2, pages 136-147.
Read now
Read now
Akane Ishihara PhD, Minoru Moriya PhD, Douglas J MacNeil PhD, Takehiro Fukami PhD & Akio Kanatani PhD. (2006) Neuropeptide Y receptors as targets of obesity treatment. Expert Opinion on Therapeutic Patents 16:12, pages 1701-1712.
Read now
Read now
Articles from other publishers (25)
Fan Xia, Lu-Ping Wen, Bing-Chen Ge, Yu-Xin Li, Fang-Ping Li & Ben-Jie Zhou. (2021) Gut microbiota as a target for prevention and treatment of type 2 diabetes: Mechanisms and dietary natural products. World Journal of Diabetes 12:8, pages 1146-1163.
Crossref
Crossref
Beatriz T. Meneguetti, Marlon H. Cardoso, Camila F.A. Ribeiro, Mário R. Felício, Ingrid B. Pinto, Nuno C. Santos, Cristiano M.E. Carvalho & Octávio L. Franco. (2019) Neuropeptide receptors as potential pharmacological targets for obesity. Pharmacology & Therapeutics 196, pages 59-78.
Crossref
Crossref
Donald E. Greydanus, Marisha Agana, Manmohan K. Kamboj, Saad Shebrain, Neelkamal Soares, Ransome Eke & Dilip R. Patel. (2018) Pediatric obesity: Current concepts. Disease-a-Month 64:4, pages 98-156.
Crossref
Crossref
Hung Pham, Hongxiang Hui, Susan Morvaridi, Jiena Cai, Sanqi Zhang, Jun Tan, Vincent Wu, Nancy Levin, Beatrice Knudsen, William A. GoddardIIIIII, Stephen J. Pandol & Ravinder Abrol. (2016) A bitter pill for type 2 diabetes? The activation of bitter taste receptor TAS2R38 can stimulate GLP-1 release from enteroendocrine L-cells. Biochemical and Biophysical Research Communications 475:3, pages 295-300.
Crossref
Crossref
Carmine Finelli. (2014) Could the improvement of obesity-related co-morbidities depend on modified gut hormones secretion?. World Journal of Gastroenterology 20:44, pages 16649.
Crossref
Crossref
Tannaz Vakilgilani, Sagen Zac-Varghese & Stephen R. Bloom. 2014. Treatment of the Obese Patient. Treatment of the Obese Patient
37
55
.
Tannaz Vakilgilani, Sagen Zac-Varghese & Stephen R. Bloom. 2014. Treatment of the Obese Patient. Treatment of the Obese Patient
37
55
.
Peter Holzer, Florian Reichmann & Aitak Farzi. (2012) Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut–brain axis. Neuropeptides 46:6, pages 261-274.
Crossref
Crossref
Shaun P. Brothers & Claes Wahlestedt. (2010) Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Molecular Medicine 2:11, pages 429-439.
Crossref
Crossref
Gopinath V. Annathur, John J. Buckley, Kevin Muthurania & Natrajan Ramasubramanyan. (2010) Application of arginine as an efficient eluent in cation exchange chromatographic purification of a PEGylated peptide. Journal of Chromatography A 1217:24, pages 3783-3793.
Crossref
Crossref
Katharine V. Hand, Christine M. Bruen, Fiona O'Halloran, Linda Giblin & Brian D. Green. (2010) Acute and chronic effects of dietary fatty acids on cholecystokinin expression, storage and secretion in enteroendocrine STC-1 cells. Molecular Nutrition & Food Research 54:S1, pages S93-S103.
Crossref
Crossref
Ishita D Majumdar & Horst C Weber. (2010) Gastrointestinal regulatory peptides and their effects on fat tissue. Current Opinion in Endocrinology, Diabetes and Obesity 17:1, pages 51-56.
Crossref
Crossref
CK Martin, H Han, SD Anton, FL Greenway & SR Smith. (2008) Effect of valproic acid on body weight, food intake, physical activity and hormones: results of a randomized controlled trial. Journal of Psychopharmacology 23:7, pages 814-825.
Crossref
Crossref
June Zhou, Roy J. Martin, Richard T. Tulley, Anne M. Raggio, Kathleen L. McCutcheon, Li Shen, Samuel Colby Danna, Sasmita Tripathy, Maren Hegsted & Michael J. Keenan. (2008) Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. American Journal of Physiology-Endocrinology and Metabolism 295:5, pages E1160-E1166.
Crossref
Crossref
Anne Ørgaard & Lotte Jensen. (2008) The Effects of Soy Isoflavones on Obesity. Experimental Biology and Medicine 233:9, pages 1066-1080.
Crossref
Crossref
Astrid A. Ortiz, Lucinda F. Milardo, Lynn B. DeCarr, Thomas M. Buckholz, Michelle R. Mays, Thomas H. Claus, James N. Livingston, Cathy D. Mahle & Kevin J. Lumb. (2007) A Novel Long-Acting Selective Neuropeptide Y2 Receptor Polyethylene Glycol-Conjugated Peptide Agonist Reduces Food Intake and Body Weight and Improves Glucose Metabolism in Rodents. Journal of Pharmacology and Experimental Therapeutics 323:2, pages 692-700.
Crossref
Crossref
Negar Sadrzadeh, Michael J. Glembourtt & Cynthia L. Stevenson. (2007) Peptide Drug Delivery Strategies for the Treatment of Diabetes. Journal of Pharmaceutical Sciences 96:8, pages 1925-1954.
Crossref
Crossref
Gabriele E SonnenbergGlenn Matfin & Rickey R Reinhardt. (2016) Review: Drug treatments for obesity: where are we heading and how do we get there?. The British Journal of Diabetes & Vascular Disease 7:3, pages 111-117.
Crossref
Crossref
m. camilleri & a. b. m. grudell. (2007) Appetite and obesity: a gastroenterologist's perspective. Neurogastroenterology & Motility 19:5, pages 333-341.
Crossref
Crossref
Kevin J. Lumb, Lynn B. DeCarr, Lucinda F. Milardo, Michelle R. Mays, Thomas M. Buckholz, Stephen E. Fisk, Carla M. Pellegrino, Astrid A. Ortiz & Cathy D. Mahle. (2007) Novel Selective Neuropeptide Y2 Receptor PEGylated Peptide Agonists Reduce Food Intake and Body Weight in Mice. Journal of Medicinal Chemistry 50:9, pages 2264-2268.
Crossref
Crossref
Lynn B. DeCarr, Thomas M. Buckholz, Lucinda F. Milardo, Michelle R. Mays, Astrid Ortiz & Kevin J. Lumb. (2007) A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice. Bioorganic & Medicinal Chemistry Letters 17:7, pages 1916-1919.
Crossref
Crossref
Ambikaipakan Balasubramaniam, Rashika Joshi, Chunhua Su, Lou Ann Friend & J. Howard James. (2007) Neuropeptide Y (NPY) Y2 receptor-selective agonist inhibits food intake and promotes fat metabolism in mice: Combined anorectic effects of Y2 and Y4 receptor-selective agonists. Peptides 28:2, pages 235-240.
Crossref
Crossref
Lynn B. DeCarr, Thomas M. Buckholz, Philip D.G. Coish, Zahra Fathi, Stephen E. Fisk, Michelle R. Mays, Stephen J. O’Connor & Kevin J. Lumb. (2007) Identification of selective neuropeptide Y2 peptide agonists. Bioorganic & Medicinal Chemistry Letters 17:2, pages 538-541.
Crossref
Crossref
Martin O Weickert, Manja Reimann, Bärbel Otto, Wendy L Hall, Katherina Vafeiadou, Jesper Hallund, Marika Ferrari, Duncan Talbot, Francesco Branca, Susanne Bügel, Christine M Williams, Hans-Joachim Zunft & Corinna Koebnick. (2006) Soy isoflavones increase preprandial peptide YY (PYY), but have no effect on ghrelin and body weight in healthy postmenopausal women. Journal of Negative Results in BioMedicine 5:1.
Crossref
Crossref
Manuela Belén Silveira Rodríguez, Antonio Gómez-Pan & Raffaele Carraro Casieri. (2006) Nuevas perspectivas en el tratamiento de la obesidad: el aparato digestivo como órgano endocrino. Medicina Clínica 127:8, pages 300-305.
Crossref
Crossref